Last reviewed · How we verify

budesonode bid + terbutaline 'as needed' — Competitive Intelligence Brief

budesonode bid + terbutaline 'as needed' (budesonode bid + terbutaline 'as needed') competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid + Beta-2 adrenergic receptor agonist. Area: Respiratory.

phase 3 Corticosteroid + Beta-2 adrenergic receptor agonist Beta-2 adrenergic receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

budesonode bid + terbutaline 'as needed' (budesonode bid + terbutaline 'as needed') — AstraZeneca. Budesonide is a corticosteroid that reduces inflammation, while terbutaline is a beta-2 adrenergic receptor agonist that relaxes airway muscles.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
budesonode bid + terbutaline 'as needed' TARGET budesonode bid + terbutaline 'as needed' AstraZeneca phase 3 Corticosteroid + Beta-2 adrenergic receptor agonist Beta-2 adrenergic receptor
Akovaz EPHEDRINE marketed Norepinephrine Releasing Agent Beta-2 adrenergic receptor 2016-01-01
Striverdi Respimat OLODATEROL Boehringer Ingelheim marketed beta2-Adrenergic Agonist Beta-2 adrenergic receptor 2014-01-01
Breo Ellipta VILANTEROL Glaxo Grp Ltd marketed beta2-Adrenergic Agonist Beta-2 adrenergic receptor 2013-01-01
Arcapta Neohaler INDACATEROL Novartis marketed beta2-Adrenergic Agonist Beta-2 adrenergic receptor 2011-01-01
Brovana ARFORMOTEROL Lupin marketed beta2-Adrenergic Agonist Beta-2 adrenergic receptor 2006-01-01
Foradil FORMOTEROL Novartis marketed beta2-Adrenergic Agonist Beta-2 adrenergic receptor 2001-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Corticosteroid + Beta-2 adrenergic receptor agonist class)

  1. AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). budesonode bid + terbutaline 'as needed' — Competitive Intelligence Brief. https://druglandscape.com/ci/budesonode-bid-terbutaline-as-needed. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: